Drug Profile


Alternative Names: IDR-1; Innate defense regulator-1; SGX-94; SGX-942; SGX-943

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of British Columbia
  • Developer Soligenix; The Childrens Hospital of Philadelphia; University of British Columbia
  • Class Anti-inflammatories; Antibacterials; Peptides; Proteins
  • Mechanism of Action Immunomodulators; SQSTM1-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders; Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Stomatitis
  • Preclinical Acute radiation syndrome; Lymphoproliferative disorders; Melioidosis
  • No development reported Bacterial infections

Most Recent Events

  • 20 Sep 2017 Soligenix receives SBIR grant from National Institute of Dental and Craniofacial Research for dusquetide development in Stomatitis (Chemoradiation therapy-induced)
  • 27 Jul 2017 Phase-III clinical trials in Stomatitis (Chemotherapy-induced) in USA (IV)
  • 03 May 2017 Soligenix plans the pivotal phase III IDR-OM-02 trial for Stomatitis in Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top